Arrayus’ Focused Ultrasound System Approved in Canada for Uterine Fibroid Ablation

October 8, 2024—Canada-based Arrayus Technologies Inc. recently announced that its MRI-guided focused ultrasound system has been granted approval by Health Canada for the ablation of uterine fibroid tissue.

According to the company, the system offers a safe, noninvasive alternative to traditional surgical options for this condition. The approval comes after the success of its first-in-human clinical trial.

The company stated that the Arrayus focused ultrasound system uses high-precision acoustic energy to target and treat tissue deep within the body without the need for incisions or general anesthesia. The system is built with a fully phased array, intuitive treatment planning tools, and real-time therapy monitoring. It enables clinicians to tailor treatments based on individual disease characteristics, ensuring precision while protecting nearby healthy tissue.

Arrayus advised it is expanding the potential applications for its focused ultrasound platform with clinical trials underway to evaluate the use of its system in various oncological settings. Additionally, the company is working with health care professionals, researchers, and industry partners to explore its use in neurology, women’s health, and other areas.

The company is currently seeking its first institutional round of funding to support commercialization and growth of its platform, noted the press release from Arrayus.